Subconjunctival bevacizumab for corneal neovascularization

Acta Ophthalmologica

Volumn 88, Issue 8, 2010, Pages 868-871

  Zaki, Ahmed A ^a   Farid, Samar F ^b  

^a RESEARCH INSTITUTE OF OPHTHALMOLOGY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Avastin ; bevacizumab; corneal neovascularization; subconjunctival

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CORNEA NEOVASCULARIZATION; CORNEA ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; MALE; MORPHOLOGY; OUTCOME ASSESSMENT; PHOTOGRAPHY; PRIORITY JOURNAL; SLIT LAMP; TREATMENT DURATION; ULCER HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PHOTOGRAPHY; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 78649832445     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01585.x     Document Type: Article

References (21)

1. Avery RL, Pieramicini DJ, Rabena MD, Castellarin AC, Nasir MA, &, Giust MJ, (2006): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372.
2. Awadein A, (2007): Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 33: 1991-1993.
3. Bahar I, Kaiserman I, McAllum P, Rootman D, &, Slomovic A, (2008a): Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27: 142-147.
4. Bahar I, Kaiserman I, McAllum P, Rootman D, &, Slomovic A, (2008b): Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33: 23-28.
5. Barros LF, &, Belfort R Jr, (2007): The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea. An Acad Bras Cienc 79: 389-394.
6. Bock F, König Y, Kruse F, Baier M, &, Cursiefen C, (2008): Bevacizumab (Avastin) eyedrops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246: 281-284.
7. Castro MR, Lutz D, &, Edelman JL, (2004): Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 79: 275-285.
8. DeStafeno J, &, Kim T, (2007): Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125: 834-836.
9. Emmanouilides C, Pegran M, Robinson R, Hecht R, &, Isacoff W, (2004): Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third-line treatment for colorectal cancer. Tech Coloproctol 8 (Suppl.): 50-52.
10. Erdurmus M, &, Totan Y, (2007): Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245: 1577-1579.
11. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, &, Noori F, (2007): Bevacizumab inhibits corneal neovascularization in an alkali burn-induced model of corneal angiogenesis. Clin Experiment Ophthalmol 35: 745-748.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
13. Kabbinavar FI, Meropol NJ, Lieberman G, Griffing S, &, Bergsland E, (2003): Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
14. Kwon YS, &, Kim JC, (2006): Inhibition of corneal neovascularization by rapamycin. Exp Mol Med 38: 173-179.
15. Lavie G, Mandel M, Hazan S, Barliya T, Blank M, Grunbaum A, Meruelo D, &, Solomon A, (2005): Antiangiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis 8: 35-42.
16. Liu Y, Cao J, Renard RA, et al. (2006): Low-dose, subconjunctival administration of VEGF trap inhibits suture-induced corneal neovascularization and inflammation. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Fort Lauderdale, FL, 30 April-4 May 2006. Rockville, MD: ARVO.
17. Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim M, Ren M, Lake J, &, Chévez-Barrios P, (2007): Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91: 804-807.
18. Michels S, Rosenfeld PJ, Pucoafito CA, Marcus EN, &, Venkatraman AS, (2005): Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: 12-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 1035-1047.
19. Riazi-Esfahani M, Peyman GA, Aydin E, Kazi AA, Kivilcim M, &, Sanders DR, (2006): Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea 25: 801-805.
20. Uy HS, Chan PS, &, Ang RE, (2008): Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 27: 70-73.
21. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt K, &, Szurman P, (2008): Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 86: 322-328.